Overview

Rituximab Maintenance After Autologous Transplantation

Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research is to see if Rituxan (rituximab) therapy given after high dose chemotherapy and transplant of a patients own stem cells will prevent or delay the return of the lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genentech, Inc.
Treatments:
Rituximab